Department of Biochemistry and Molecular Biology, Kunming Medical University, Kunming, 650500, Yunnan Province, China.
Department of Microbiology and Immunology, Kunming Medical University, Kunming, 650500, Yunnan Province, China.
BMC Cancer. 2020 Jul 22;20(1):682. doi: 10.1186/s12885-020-07188-3.
Long intergenic non-coding RNA 00511 (LINC00511) is highly expressed in diverse cancers and has a correlation with poor clinical outcomes for cancer patients. In view of contradictory data among published data, we aim to evaluate the prognostic role of LINC00511 for cancer patients.
In the present study, a meta-analysis of related studies has been performed to investigate the prognostic significance of LINC00511 in cancer patients. Relevant studies published before December 22, 2019 were systematically searched online in PubMed, EMBASE, Web of Science, and the Cochrane Library databases. The relationship between LINC00511 expression and cancer patients' survival, including overall survival (OS), disease-free survival (DFS)/relapse-free survival (RFS) and progression-free survival (PFS), was evaluated using pooled hazard ratios (HRs) with their corresponding 95% confidence intervals (CIs). The association between LINC00511 expression and clinicopathological features was assessed using odd ratios (ORs) and their corresponding 95% CIs.
A total of 14 eligible studies with 1883 patients were enrolled in the present meta-analysis. The results demonstrated that elevated expression of LINC00511 was significantly associated with poor OS (HR = 2.62; 95% CI: 2.00-3.45; p < 0.001), PFS (HR = 1.80; 95% CI: 1.29-2.51; p = 0.001) and DFS/RFS (HR = 2.90; 95% CI: 1.04-8.12; p = 0.04). Additionally, High LINC00511 expression was associated with large tumor size (OR = 3.10; 95% CI: 1.97-4.86; p < 0.00001), lymph node metastasis (OR = 3.11; 95% CI: 2.30-4.21; p < 0.00001), advanced clinical stage (OR = 3.95; 95% CI: 2.68-5.81; p < 0.00001), distant metastasis (OR = 2.39; 95% CI: 1.16-4.93; p = 0.02), and disease recurrence (OR = 4.62; 95% CI: 2.47-8.65; p < 0.00001). Meanwhile, no correlation was found between LINC00511 expression and age, gender, and histological grade. These findings were consolidated by the results of bioinformatics analysis.
Based on our findings, LINC00511 may serve as a novel prognostic biomarker for cancer patients.
长链非编码 RNA 00511（LINC00511）在多种癌症中高表达，并与癌症患者的临床结局不良相关。鉴于已发表数据之间存在矛盾，我们旨在评估 LINC00511 对癌症患者的预后作用。
本研究通过荟萃分析相关研究，以评估 LINC00511 在癌症患者中的预后意义。系统地检索了 PubMed、EMBASE、Web of Science 和 Cochrane 图书馆数据库中截至 2019 年 12 月 22 日之前发表的相关研究。使用合并的风险比（HR）及其相应的 95%置信区间（CI）来评估 LINC00511 表达与癌症患者生存（包括总生存（OS）、无病生存（DFS）/无复发生存（RFS）和无进展生存（PFS））之间的关系。使用比值比（OR）及其相应的 95%CI 评估 LINC00511 表达与临床病理特征之间的关联。
本荟萃分析共纳入了 14 项符合条件的研究，共包含 1883 例患者。结果表明，LINC00511 表达升高与较差的 OS（HR=2.62；95%CI：2.00-3.45；p<0.001）、PFS（HR=1.80；95%CI：1.29-2.51；p=0.001）和 DFS/RFS（HR=2.90；95%CI：1.04-8.12；p=0.04）显著相关。此外，LINC00511 高表达与肿瘤较大（OR=3.10；95%CI：1.97-4.86；p<0.00001）、淋巴结转移（OR=3.11；95%CI：2.30-4.21；p<0.00001）、临床分期较晚（OR=3.95；95%CI：2.68-5.81；p<0.00001）、远处转移（OR=2.39；95%CI：1.16-4.93；p=0.02）和疾病复发（OR=4.62；95%CI：2.47-8.65；p<0.00001）相关。同时，LINC00511 表达与年龄、性别和组织学分级之间无相关性。这些发现通过生物信息学分析得到了证实。
根据我们的研究结果，LINC00511 可能成为癌症患者的一种新的预后生物标志物。
